Tryptophan Catabolites and Their Impact on Multiple Sclerosis Progression

Author(s): Jens O. Watzlawik, Bharath Wootla, Moses Rodriguez

Journal Name: Current Pharmaceutical Design

Volume 22 , Issue 8 , 2016

Become EABM
Become Reviewer


Accumulating evidence demonstrates involvement of tryptophan metabolites and in particular activation of the kynurenine pathway (KP) in neurocognitive disorders under CNS inflammatory conditions. The KP is involved in several brain-associated disorders including Parkinson’s disease, AIDS dementia, Alzheimer’s disease, Huntington’s disease, amyotrophic lateral sclerosis, schizophrenia, and brain tumors. Our review is an attempt to address any relevant association between dysregulation of KP and multiple sclerosis (MS), an inflammatory CNS disorder that ultimately leads to demyelinated brain areas and severe neurological deficits. Modulation of KP is a new topic for the field of MS and warrants further research. The availability of potential KP modulators approved for MS may shed some light into the therapeutic potential of KP antagonists for the treatment of MS patients.

Keywords: Demyelination, microglia, macrophages, kynurenine pathway, quinolinic acid, kynurenic acid.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Page: [1049 - 1059]
Pages: 11
DOI: 10.2174/1381612822666151215095940
Price: $65

Article Metrics

PDF: 45